Preview: Phathom Pharmaceuticals's Earnings
Portfolio Pulse from Benzinga Insights
Phathom Pharmaceuticals (NASDAQ:PHAT) is scheduled to release its quarterly earnings report on March 7, 2024, with an estimated EPS of $-1.08. Analysts and investors will be closely watching for any positive guidance for the next quarter, as past performance shows mixed reactions to earnings reports. Shares have risen 19.3% over the last 52 weeks, indicating a generally positive outlook from long-term shareholders.
March 06, 2024 | 4:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Phathom Pharmaceuticals is expected to report an EPS of $-1.08 for the latest quarter. Historical data shows mixed stock price reactions to past earnings reports. With shares up 19.3% over the last year, the upcoming earnings and particularly the guidance for the next quarter could significantly influence the stock's short-term performance.
The expected EPS of $-1.08 sets a cautious tone, but the company's history of beating estimates and the stock's positive year-over-year performance suggest potential for a neutral to positive reaction, depending on the guidance provided. However, the mixed reactions to past earnings highlight the uncertainty and the importance of forward-looking statements in influencing investor sentiment.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100